National Institute for Health and Care Excellence (NICE). NICE technology appraisal guidance 285. Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer. 2013.

National Institute for Health and Care Excellence (NICE). Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second line or subsequent treatment of advanced ovarian cancer. 2005.

Macmillan sites

Bookmark this page

Macmillan Cancer Support, registered charity in England and Wales (261017), Scotland (SC039907) and the Isle of Man (604). A company limited by guarantee, registered in England and Wales company number 2400969. Isle of Man company number 4694F. Registered office: 89 Albert Embankment, London SE1 7UQ.